Zumutor is a biotechnology company focused on developing immuno-oncology therapies that harness the body's innate immune system to treat cancer. The company specializes in the discovery and development of therapeutic antibodies designed to activate natural killer (NK) cells and modulate the tumor microenvironment. Its proprietary INABLR® antibody discovery platform supports the identification and optimization of novel antibody candidates for oncology applications. Zumutor is advancing a pipeline of monoclonal antibody therapies, including ZM008, which targets immune checkpoint pathways involved in tumor immune evasion and is being evaluated for the treatment of solid tumors. In addition to its internal drug development programs, the company provides antibody discovery and development capabilities that support the creation of next-generation biologic therapies.